Moreover, decreased SREBP-1 was a risk factor for CAD, independent of histories of hyperlipidemia, diabetes, hypertension and medication of Statins, which suggest SREBP-1 might be involved in the pathogenesis of CAD through unconventional regulatory network which still need to be clarified with large sample size in future. Here, SREBF1 is linked to hypertensive disorder.